Cti Biopharma Corp Sample Contracts

Cti Biopharma Corp – TERMINATION AND TRANSFER AGREEMENT THIS TERMINATION AND TRANSFER AGREEMENT (the “Termination and Transfer Agreement”) is effective as of November 1st, 2018 and between LES LABORATOIRES SERVIER, a company duly organized and existing under the laws of France, having offices and principal place of business at 50 Rue Carnot, 92284 Suresnes Cedex, France and INSTITUT DE RECHERCHES INTERNATIONALES SERVIER, a company duly organized and existing under the laws of France, having offices and principal place of business at 50 Rue Carnot, 92284 Suresnes Cedex, France together, hereinafter referred to as “ (February 27th, 2019)
Cti Biopharma Corp – CTI BioPharma Receives $10 Million Milestone Payment for TRISENOX® SEATTLE, Feb. 11, 2019 - CTI BioPharma Corp. (NASDAQ:CTIC) today announced that it has received a $10 million milestone payment from Teva Pharmaceutical Industries Ltd. related to the achievement of sales milestones for TRISENOX® (arsenic trioxide). TRISENOX was acquired from CTI BioPharma by Cephalon, Inc. (Cephalon). Cephalon was subsequently acquired by Teva. The milestone was paid pursuant to an acquisition agreement for TRISENOX entered into with Cephalon under which CTI BioPharma is eligible to receive up to an additional (February 11th, 2019)
Cti Biopharma Corp – syndrome (MDS), chronic myelomonocytic leukemia (CMML), and chronic lymphocytic leukemia (CLL), due to its inhibition of c-fms, IRAK1, JAK2 and FLT3. About CTI BioPharma Corp. CTI BioPharma Corp. is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies covering a spectrum of blood-related cancers that offer a unique benefit to patients and healthcare providers. The CTI BioPharma lead product candidate, pacritinib, is being developed for the treatment of patients with myelofibrosis. CTI BioPharma is headquartered in Seattle, Washin (February 1st, 2019)
Cti Biopharma Corp – Forward Looking Statement This presentation includes forward-looking statements within the meaning of the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are subject to a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results and the trading price of CTI BioPharma's securities. Such statements include, but are not limited to, expectations with respect to results from PAC203, our ability to establish a dose for our randomized Phase 3 study of pacritinib, and our ability to commence sa (January 3rd, 2019)
Cti Biopharma Corp – CTI BIOPHARMA CORP. COMMON STOCK SALES AGREEMENT (November 1st, 2018)
Cti Biopharma Corp – CTI BIOPHARMA CORP. AMENDMENT TO EMPLOYMENT AGREEMENT (November 1st, 2018)

This Amendment to Employment Agreement (this “Amendment”) is made by and between Adam R. Craig (“Executive”) and CTI BioPharma Corp., a Delaware corporation (the “Company” and together with Executive, the “Parties”) on the dates set forth below.

Cti Biopharma Corp – SEPARATION AGREEMENT AND RELEASE This Separation Agreement and Release (“Agreement”) is made by and between Jack Singer (“Employee”) and CTI BioPharma Corp. (the “Company”) (collectively referred to as the “Parties” or individually referred to as a “Party”). WHEREAS, Employee was employed at-will by the Company, subject to the terms of a Severance Agreement between Employee and the Company dated January 6, 2015 (the “Severance Agreement”); WHEREAS, Employee signed an Employee Invention and Proprietary Information with the Company (the “Confidentiality Agreement”); WHEREAS, the Company previous (September 6th, 2018)
Cti Biopharma Corp – Forward Looking Statement This presentation includes forward-looking statements within the meaning of the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are subject to a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results and the trading price of CTI BioPharma's securities. Such statements include, but are not limited to, expectations with respect to the timing and planned enrollment of and interim analysis for PAC203, our ability to commence a randomized Phase 3 study of pacriti (August 15th, 2018)
Cti Biopharma Corp – FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT (August 3rd, 2018)

This First Amendment to Loan and Security Agreement (this “Amendment”) is entered into this 17th day of May, 2018 by and between SILICON VALLEY BANK (“Bank”) and CTI BIOPHARMA CORP., a Delaware corporation (which assumed the obligations of CTI BioPharma Corp., a Washington corporation) (“Borrower”), whose address is 3101 Western Avenue, #600, Seattle, Washington 98121.

Cti Biopharma Corp – August 2, 2018 U.S. Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 Re: CTI BioPharma Corp. File No. 001-12465 Commissioners: We have read the statement made by CTI BioPharma Corp. under Item 4.01 of its Form 8-K/A as an amendment (“Amendment No. 1”) dated August 2, 2018 to the Current Report on Form 8-K dated July 13, 2018 filed by CTI BioPharma Corp. on July 19, 2018. We agree with the statement concerning our Firm in Amendment No. 1; we are not in a position to agree or disagree with other statements of CTI BioPharma Corp. contained therein. Very truly yours, Marcum (August 3rd, 2018)
Cti Biopharma Corp – CTI BIOPHARMA CORP. 2017 EQUITY INCENTIVE PLAN STOCK OPTION AGREEMENT (GLOBAL FORM) (May 21st, 2018)

THIS STOCK OPTION AGREEMENT, including any country-specific appendices attached hereto, (collectively the “Option Agreement”) is dated as of ______________ (the “Grant Date”) by and between CTI BioPharma Corp., a Delaware corporation (the “Corporation”), and ____________________ (the “Participant”). Capitalized terms used herein and not otherwise defined shall have the meaning assigned to such terms in the Plan.

Cti Biopharma Corp – CTI BIOPHARMA CORP. AMENDED AND RESTATED 2017 EQUITY INCENTIVE PLAN (May 21st, 2018)
Cti Biopharma Corp – AMENDED AND RESTATED BYLAWS OF CTI BIOPHARMA CORP. a Delaware corporation (March 23rd, 2018)
Cti Biopharma Corp – WAIVER AGREEMENT (March 7th, 2018)

This Waiver Agreement (this “Waiver”) is entered into this 19th day of January, 2018, by and between SILICON VALLEY BANK (“Bank”) and CTI BIOPHARMA CORP., a Washington corporation (“Borrower”) whose address is 3101 Western Avenue, #800, Seattle, Washington 98121.

Cti Biopharma Corp – STOCK EXCHANGE AGREEMENT (February 12th, 2018)

This STOCK EXCHANGE AGREEMENT, is dated as of February 8, 2018 (this “Agreement”), by and between CTI BIOPHARMA CORP., a Delaware corporation (the “Issuer”) and BVF PARTNERS L.P. (the “Holder”).

Cti Biopharma Corp – CTI BIOPHARMA CORP. (February 12th, 2018)

CTI BIOPHARMA CORP., Delaware corporation (the “Corporation”), in accordance with the provisions of Section 103 of the Delaware General Corporation Law (the “DGCL”) does hereby certify that, in accordance with Sections 141(c) and 151 of the DGCL, the following resolution was duly adopted by a committee of the Board of Directors of the Corporation acting upon authority delegated by the Board of Directors, on February 7, 2018:

Cti Biopharma Corp – 20,000,000 Shares CTI BioPharma Corp. Common Stock UNDERWRITING AGREEMENT (February 12th, 2018)
Cti Biopharma Corp – The IR S requires that w e report the cost basis of certain shares acquired after January 1, 2011. If your shares w ere covered by the legislation and you have sold or transferred the shares and requested a specific cost basis calculation m ethod, w e have processed as requested. If you did not specify a cost basis calculation m ethod, w e have defaulted to the first in, first out (FIFO ) m ethod. P lease visit our w ebsite or consult your tax advisor if you need additional inform ation about cost basis. If you do not keep in con tact with us or do not have an y activity in your account for th (February 12th, 2018)
Cti Biopharma Corp – INDEMNIFICATION AGREEMENT (January 24th, 2018)

This Indemnification Agreement ("Agreement"), dated as of the Effective Date, is entered by and between CTI BioPharma Corp., a Delaware corporation (the "Company"), and ______________ ("Indemnitee"). This Agreement supersedes and replaces any and all previous Agreements between the Company and Indemnitee covering the subject matter of this Agreement.

Cti Biopharma Corp – BYLAWS OF CTI BIOPHARMA CORP. a Delaware corporation (January 24th, 2018)
Cti Biopharma Corp – CERTIFICATE OF INCORPORATION OF CTI BIOPHARMA CORP. (January 24th, 2018)

The undersigned, for the purpose of organizing a corporation under the General Corporation Law of the State of Delaware, certifies:

Cti Biopharma Corp – AGREEMENT AND PLAN OF MERGER (January 24th, 2018)

This AGREEMENT AND PLAN OF MERGER (this Agreement), dated as of January 24, 2018, is entered into by and between CTI BioPharma Corp., a Delaware corporation (the Delaware Corporation), and CTI BioPharma Corp., a Washington corporation (the Washington Corporation).

Cti Biopharma Corp – PRESS RELEASE (January 18th, 2018)

CTI Biopharma Corp. discloses expected effective date of the merger and MTA delisting, subject to shareholder approval at the shareholders’ meeting

Cti Biopharma Corp – Forward Looking Statement This presentation includes forward-looking statements within the meaning of the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are subject to a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results and the trading price of CTI BioPharma's securities. Such statements include, but are not limited to, expectations with respect to the timing and planned enrollment of and interim analysis for PAC203 and submission of responses to Day 120 list of questions, and (January 5th, 2018)
Cti Biopharma Corp – EXHIBIT B IN THE SUPERIOR COURT OF THE STATE OF WASHINGTON IN AND FOR KING COUNTY KEVIN HAMMOND, Derivatively And On Behalf of CTI BIOPHARMA CORP., Plaintiff, v. JAMES A. BIANCO, LOUIS A. BIANCO, JACK W. SINGER, BRUCE J. SEELEY, JOHN H. BAUER, PHILLIP M. NUDELMAN, REED V. TUCKSON, KAREN IGNAGNI, RICHARD L. LOVE, MARY O. MUNDINGER, and FREDERICK W. TELLING, Defendants, and CTI BIOPHARMA CORP., Nominal Defendant. NO. 16-2-05818-3 SEA MAURIO ELEY, Derivatively And On Behalf of CTI BIOPHARMA CORP., Plaintiff, v. JAMES A. BIANCO, LOUIS A. BIANCO, JACK W. SINGER, BRUCE J. SEELEY, JOHN H. BAUER, PHIL (December 15th, 2017)
Cti Biopharma Corp – 3101 WESTERN AVENUE (December 5th, 2017)
Cti Biopharma Corp – Contract (November 28th, 2017)

THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER, SUCH OFFER, SALE, PLEDGE OR OTHER TRANSFER IS EXEMPT FROM SUCH REGISTRATION.

Cti Biopharma Corp – Contract (November 28th, 2017)

THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER, SUCH OFFER, SALE, PLEDGE OR OTHER TRANSFER IS EXEMPT FROM SUCH REGISTRATION.

Cti Biopharma Corp – LOAN AND SECURITY AGREEMENT (November 28th, 2017)

THIS LOAN AND SECURITY AGREEMENT (this “Agreement”) dated as of November 28, 2017 (the “Effective Date”) between SILICON VALLEY BANK, a California corporation with a loan production office located at 505 Howard Street, 3rd Floor, San Francisco, CA 94105 (“Bank”), and CTI BIOPHARMA CORP., a Washington corporation (“Borrower”), provides the terms on which Bank shall lend to Borrower and Borrower shall repay Bank. The parties agree as follows:

Cti Biopharma Corp – Forward Looking Statement This presentation includes forward-looking statements within the meaning of the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are subject to a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results and the trading price of CTI BioPharma's securities. Such statements include, but are not limited to, expectations with respect to the timing and planned enrollment of PAC203 and our ability to interpret clinical trial data and results for PERSIST-2 despite not (November 13th, 2017)
Cti Biopharma Corp – FIFTH AMENDMENT TO LOAN AND SECURITY AGREEMENT (November 7th, 2017)

This FIFTH AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Amendment”), dated as of August 4, 2017, but effective as of July 31, 2017 (the “Fifth Amendment Date”), is by and among CTI BIOPHARMA CORP., a Washington corporation formerly known as, CELL THERAPEUTICS, INC., (“CTI”) (“Borrower”), HERCULES CAPITAL, INC., a Maryland corporation (“HC”), in its capacity as administrative agent for itself and the Lender (in such capacity, the “Agent”), the Lenders otherwise a party hereto from time to time including HC in its capacity as a Lender and assignee of HERCULES CAPITAL FUNDING TRUST 2012-1, and HERCULES CAPITAL FUNDING TRUST 2014 (“2014 Trust”), assignee of HERCULES CAPITAL FUNDING 2014-1 LLC, assignee of HC (2014 Trust and HC collectively, referred to as, “Lender”).

Cti Biopharma Corp – SEVERANCE AGREEMENT (September 26th, 2017)

THIS SEVERANCE AGREEMENT (this “Agreement”) is made and entered into this 25th day of September, 2017 (the “Effective Date”), by and between CTI BioPharma Corp., a Washington corporation (the “Company”), and David Kirske (the “Executive”).

Cti Biopharma Corp – FOURTH AMENDMENT TO SHAREHOLDER RIGHTS AGREEMENT (September 26th, 2017)

This FOURTH AMENDMENT TO SHAREHOLDER RIGHTS AGREEMENT is made and entered into as of September 22, 2017 (this “Amendment”), between CTI BioPharma Corp., a Washington corporation, and Computershare Trust Company, N.A., a federally chartered trust company (the “Rights Agent”). The capitalized terms used and not otherwise defined herein have the respective meanings given to them in that certain Shareholder Rights Agreement, between the Company and the Rights Agent, dated as of December 28, 2009, as amended by that certain First Amendment to Shareholder Rights Agreement, between the Company and the Rights Agent, dated August 31, 2012, as further amended by that certain Second Amendment to Shareholder Rights Agreement, between the Company and the Rights Agent, dated December 6, 2012, and as further amended by that certain Third Amendment to Shareholder Rights Agreement, between the Company and the Rights Agent, dated December 1, 2015 (as so amended, the “Rights Agreement”).

Cti Biopharma Corp – FOURTH AMENDMENT TO SHAREHOLDER RIGHTS AGREEMENT (September 26th, 2017)

This FOURTH AMENDMENT TO SHAREHOLDER RIGHTS AGREEMENT is made and entered into as of September 22, 2017 (this “Amendment”), between CTI BioPharma Corp., a Washington corporation, and Computershare Trust Company, N.A., a federally chartered trust company (the “Rights Agent”). The capitalized terms used and not otherwise defined herein have the respective meanings given to them in that certain Shareholder Rights Agreement, between the Company and the Rights Agent, dated as of December 28, 2009, as amended by that certain First Amendment to Shareholder Rights Agreement, between the Company and the Rights Agent, dated August 31, 2012, as further amended by that certain Second Amendment to Shareholder Rights Agreement, between the Company and the Rights Agent, dated December 6, 2012, and as further amended by that certain Third Amendment to Shareholder Rights Agreement, between the Company and the Rights Agent, dated December 1, 2015 (as so amended, the “Rights Agreement”).

Cti Biopharma Corp – SEPARATION AND RELEASE AGREEMENT (August 22nd, 2017)

This Separation and Release Agreement (this “Agreement”) is entered by and between Matthew Plunkett (“Executive”) and CTI BioPharma Corp., a Washington corporation (the “Company”), on this 22nd day of August, 2017 (the “Effective Date”).